Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Junjie GU, Fan BAI, Lan SONG, Yingyi WANG
Formato: article
Lenguaje:ZH
Publicado: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021
Materias:
epidermal growth factor receptor
interstitial lung disease
lung neoplasms
osimertinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/08ac61b7c38540368ddbabbcc8b08745
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/08ac61b7c38540368ddbabbcc8b08745

Ejemplares similares